Head of Prostate Biopsy @uniklinik_hd - clinician scientist @dkfz , boy dad, coffee enthusiast
Heidelberg, Germany
Joined January 2010
- Tweets2.3K
- Following2K
- Followers447
- Likes132
Dr. Fabian Falkenbach retweeted
There's more than Will Rogers to consider. PSMA-PET depicts a different disease state. @piet_ost There is also asymmetric utility in rule-in and rule-out for randomising (Rx escalation) @IP_London @declangmurphy @DrMHofman only a randomised study like AVIDITY will satisfy all 🙏
Dr. Fabian Falkenbach retweeted
Local salvage therapies alone for #ProstateCancer recurrence after radiotherapy maintained >75% androgen deprivation therapy–free survival at 2 years with manageable rates of severe adverse events, supporting their use in selected patients. ja.ma/4aQLVz6
Dr. Fabian Falkenbach retweeted
My first paper with Alex and it's a doozy (also jay, canes, QDT)
$ISRG and others stealing our IP. We have issues – at McLean, VA
Who really owns robotic surgery data?
The platform (not the surgeon) records every move in HD + telemetry, building massive AI datasets.
Surgeons create it. Patients rarely consent to its downstream use. But the platform owns the data?
We express our concerns in this @EUplatinum editorial:
authors.elsevier.com/a/1nIw0…
@daviesbj @CanesDavid @qdtrinh @JSimhan
Dr. Fabian Falkenbach retweeted
Among men with locally advanced prostate cancer, transdermal estradiol was noninferior to LHRH agonists for 3-year metastasis-free survival and led to a lower incidence of hot flashes but a higher incidence of gynecomastia. Full results of the STAMPEDE-1 and PATCH trials: nejm.org/doi/full/10.1056/NE…
ALT Original Article | Mar 25, 2026 Transdermal Estradiol Patches in Locally Advanced Prostate Cancer Figure 2A. Metastasis-free Survival
Dr. Fabian Falkenbach retweeted
A clinical trial co-led by Peter Mac has shown a way to reduce the need for invasive biopsies to check for prostate cancer.
It found PSMA PET/CT scanning could halve the number of people requiring a biopsy, without missing any harmful cancers.
More: petermac.org/about-us/news-a…
Dr. Fabian Falkenbach retweeted
📣@ChapinMD presents best systemic therapy trial +/- prostatectomy n=120 randomised phase II trial in #prostatecancer. No observed benefit for prostatectomy 🔪🩸. Ongoing recruitment for SWOG-1802, pls support this important clinical trial 👏🏽#pcsm #EAU26
Dr. Fabian Falkenbach retweeted
🚨 PORTAL nomogram for PSMA PET–staged oligorecurrent #prostatecancer
@TheLancetOncol
🎯 Predicts ADT-free survival after MDT
🔑 signals:
1⃣↑ pre-MDT PSA
2⃣Short PSA-DT
3⃣3–5 lesions
4⃣M1 disease
📊 2-yr ADT-free survival:
🟢 Low risk: 84%
🟡 Intermediate: 71%
🔴 High risk: 45%
C-index ~0.66 → modest individual prediction, useful group stratification.
⭐️Risk-adapted MDT decision-making just got sharper
🔗shorturl.at/KqOod
@urotoday @UrologyTimes @PCFnews
Dr. Fabian Falkenbach retweeted
2026 @AmericanCancer Statistics are out. #prostatecancer is now #1 in incidence for all US ppl. Mortality numbers also up though ASR is slightly down; mortality still >2x for Black men.
New USPSTF guidelines expected this year… Get screened!!
cancer.org/content/dam/cance…
Dr. Fabian Falkenbach retweeted
Cribriform morphology predicted 15-year metastasis in #ProstateCancer, with radiotherapy plus neoadjuvant ADT reducing this risk, while cribriform-negative patients did not benefit from early radical treatment for metastasis prevention. ja.ma/45q1pYb
Dr. Fabian Falkenbach retweeted
Ending the Inequality—Why Men with Prostate Cancer and ADT suffer from hot flushes when women have access to effective therapy? When the industry discriminates against male patients. @PblanchardMD, @AnthonyMJoshua, @Silke_Gillessen, @PedraniMartino sciencedirect.com/science/ar…
Dr. Fabian Falkenbach retweeted
Our overview of and guidance for performance measures to evaluate medical AI is finally out!
- Stop bashing AUROC
- Calibration + clinical utility are key
- Plot risk distributions
- Classification measures are improper
thelancet.com/journals/landi…
Dr. Fabian Falkenbach retweeted
MRI is a great tool in prostate cancer. The problem is, quality in practice might not be quality we see in studies. Nice study from @dr_coops showing that in the VA, MRI not good enough to rule out biopsy. jamanetwork.com/journals/jam…
Dr. Fabian Falkenbach retweeted
How much cancer is there in a prostate biopsy?
‼️Over a dozen different ways that pathologists can measure this
〽️ Lots of variability
🔀 Differential impact on treatment decisions
Great talk by Prof Glen Kristiansen
@aimhaider @daniel_berney
Dr. Fabian Falkenbach retweeted
🌙LUNAR phase 2 RCT: adding Lu-177 PSMA to SABR for oligorecurrent prostate cancer significantly improved PFS without increased toxicity
Just out in @JCO_ASCO: ascopubs.org/doi/pdf/10.1200…
Impressive trial and results @AmarUKishan @CalaisJeremie and team
Dr. Fabian Falkenbach retweeted
🧬 Why Docetaxel Works in Prostate Cancer (and Others Don’t 😮)
Not all taxanes are born equal — one cracked the prostate code 🧩
💥 Docetaxel = The AR Disruptor
•Freezes microtubules → mitotic chaos (G₂/M arrest)
•Phosphorylates Bcl-2 → flips the “self-destruct” switch
🚫 Stops androgen receptor (AR) from entering the nucleus — and that’s its secret weapon!
⚖️ Paclitaxel vs Cabazitaxel: Why They Miss the Mark?
•Paclitaxel → can’t penetrate prostate tumor microenvironment effectively ❌
•Cabazitaxel → beats resistance pumps 💪 but doesn’t block AR trafficking as powerfully
👉 Only docetaxel truly starves the tumor of AR signaling
🧠 Proof in Trials
•mCRPC: OS ↑ in TAX-327
•mHSPC: OS ↑ in CHAARTED & STAMPEDE
•Now the backbone for ARSI + PARPi combos
💡 Takeaway:
Docetaxel isn’t just chemo - it’s a molecular double agent that shuts down both cell division and androgen signaling.
🔖 Save this gem for viva, boards & clinic rounds!
#OncoTwitter #ProstateCancer #MedTwitter @myESMO @esmo_open @OncoAlert @ASCO @Uromigos
Dr. Fabian Falkenbach retweeted
Intra- and interrater agreement with the AI platform aPROMISE were substantial to almost perfect, comparable to the standard-of-care image viewing software. ow.ly/Ut5f50Xif8k
#NuclearMedicine #AI #ProstateCancer @ffmed
Dr. Fabian Falkenbach retweeted
🚨23 years of PSA screening in @NEJM 🚨
👉ERSPC RCT of >162k patients
📅Median 23 year f/u PSA screening lead to...
📉 #prostatecancer mortality by 13%
✅1 death prevented for every 456 men invited for screening or 12 diagnosed w/ PCa
📉Risk of advanced PCa by 34%
⭐️Benefit continues to rise over time as harm-benefit ratio improves
🔗shorturl.at/ajgNN
@PCF_Science @PCFnews @urotoday @UrologyTimes @renalandurology @UroOnc
Dr. Fabian Falkenbach retweeted
Exciting 23 year update from the ERSPC #prostatecancer screening trial from @MoniqueRoobol and team, and a great editorial @VickersBiostats. NND is down to 12 and still falling! And the benefit:harm ratio would be even better w/ modern screening/dx/tx pathways.
At 23 years of follow-up, population-based PSA screening of asymptomatic men led to a sustained reduction in prostate cancer mortality, although overdiagnosis remains a concern. Full ERSPC study results: nej.md/42YYsg7
Editorial: Early Detection of Prostate Cancer — Time to Fish or Cut Bait nej.md/47tKwfA
ALT Original Article | Oct 30, 2025 European Study of Prostate Cancer Screening — 23-Year Follow-up Figure 2B. Prostate Cancer–Specific Mortality. The NEJM identity sits at the bottom.
Dr. Fabian Falkenbach retweeted
The prostate cancer PSA screening story over 23 years of follow-up for >166,000 participants: more detection, small reduction of mortality @NEJM nejm.org/doi/full/10.1056/NE…
Dr. Fabian Falkenbach retweeted
Drug Approvals in 🇺🇸 for Prostate Cancer (2010-2025)
Go ahead and bookmark this beauty from @PBarataMD
@urotoday #ESMO25
